These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

128 related items for PubMed ID: 17405254

  • 1. Systemic metabolic effects of combined insulin-like growth factor-I and growth hormone therapy in patients who have sustained acute traumatic brain injury.
    Hatton J, Kryscio R, Ryan M, Ott L, Young B.
    J Neurosurg; 2006 Dec; 105(6):843-52. PubMed ID: 17405254
    [Abstract] [Full Text] [Related]

  • 2. Growth hormone.
    Matsuno A.
    J Neurosurg; 2007 May; 106(5):940; author reply 940-1. PubMed ID: 17542549
    [No Abstract] [Full Text] [Related]

  • 3. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans.
    Clemmons DR, Smith-Banks A, Underwood LE.
    J Clin Endocrinol Metab; 1992 Jul; 75(1):234-8. PubMed ID: 1619015
    [Abstract] [Full Text] [Related]

  • 4. Effects of insulin-like growth factor I combined with growth hormone on glucocorticoid-induced whole-body protein catabolism in man.
    Berneis K, Ninnis R, Girard J, Frey BM, Keller U.
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2528-34. PubMed ID: 9253329
    [Abstract] [Full Text] [Related]

  • 5. Frequent intravenous pulses of growth hormone together with glutamine supplementation in prolonged critical illness after multiple trauma: effects on nitrogen balance, insulin resistance, and substrate oxidation.
    Duska F, Fric M, Waldauf P, Pazout J, Andel M, Mokrejs P, Tůma P, Pachl J.
    Crit Care Med; 2008 Jun; 36(6):1707-13. PubMed ID: 18496372
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A.
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [Abstract] [Full Text] [Related]

  • 7. Intravenous insulin-like growth factor-I (IGF-I) in moderate-to-severe head injury: a phase II safety and efficacy trial.
    Hatton J, Rapp RP, Kudsk KA, Brown RO, Luer MS, Bukar JG, Chen SA, McClain CJ, Gesundheit N, Dempsey RJ, Young B.
    J Neurosurg; 1997 May; 86(5):779-86. PubMed ID: 9126892
    [Abstract] [Full Text] [Related]

  • 8. Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse.
    Bianda TL, Hussain MA, Keller A, Glatz Y, Schmitz O, Christiansen JS, Alberti KG, Froesch ER.
    Diabetologia; 1996 Aug; 39(8):961-9. PubMed ID: 8858219
    [Abstract] [Full Text] [Related]

  • 9. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
    Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
    [Abstract] [Full Text] [Related]

  • 10. The combination of insulin-like growth factor I and insulin-like growth factor-binding protein-3 reduces insulin requirements in insulin-dependent type 1 diabetes: evidence for in vivo biological activity.
    Clemmons DR, Moses AC, McKay MJ, Sommer A, Rosen DM, Ruckle J.
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1518-24. PubMed ID: 10770191
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone.
    Jensen PB, Hansen TB, Frystyk J, Ladefoged SD, Pedersen FB, Christiansen JS.
    Clin Nephrol; 1999 Aug; 52(2):103-9. PubMed ID: 10480221
    [Abstract] [Full Text] [Related]

  • 12. Continuous infusion versus daily injections of growth hormone (GH) for 4 weeks in GH-deficient patients.
    Laursen T, Jørgensen JO, Jakobsen G, Hansen BL, Christiansen JS.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2410-8. PubMed ID: 7543114
    [Abstract] [Full Text] [Related]

  • 13. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
    Svensson J, Lönn L, Jansson JO, Murphy G, Wyss D, Krupa D, Cerchio K, Polvino W, Gertz B, Boseaus I, Sjöström L, Bengtsson BA.
    J Clin Endocrinol Metab; 1998 Feb; 83(2):362-9. PubMed ID: 9467542
    [Abstract] [Full Text] [Related]

  • 14. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women.
    Khorram O, Laughlin GA, Yen SS.
    J Clin Endocrinol Metab; 1997 May; 82(5):1472-9. PubMed ID: 9141536
    [Abstract] [Full Text] [Related]

  • 15. Long-term effects of continuous subcutaneous infusion versus daily subcutaneous injections of growth hormone (GH) on the insulin-like growth factor system, insulin sensitivity, body composition, and bone and lipoprotein metabolism in GH-deficient adults.
    Laursen T, Gravholt CH, Heickendorff L, Drustrup J, Kappelgaard AM, Jørgensen JO, Christiansen JS.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1222-8. PubMed ID: 11238512
    [Abstract] [Full Text] [Related]

  • 16. Effects of growth hormone and insulin-like growth factor-I singly and in combination on in vivo capacity of urea synthesis, gene expression of urea cycle enzymes, and organ nitrogen contents in rats.
    Grøfte T, Wolthers T, Jensen SA, Møller N, Jørgensen JO, Tygstrup N, Orskov H, Vilstrup H.
    Hepatology; 1997 Apr; 25(4):964-9. PubMed ID: 9096605
    [Abstract] [Full Text] [Related]

  • 17. Recovery of growth hormone release from suppression by exogenous insulin-like growth factor I (IGF-I): evidence for a suppressive action of free rather than bound IGF-I.
    Chapman IM, Hartman ML, Pieper KS, Skiles EH, Pezzoli SS, Hintz RL, Thorner MO.
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2836-42. PubMed ID: 9709956
    [Abstract] [Full Text] [Related]

  • 18. Octreotide as primary therapy for acromegaly.
    Newman CB, Melmed S, George A, Torigian D, Duhaney M, Snyder P, Young W, Klibanski A, Molitch ME, Gagel R, Sheeler L, Cook D, Malarkey W, Jackson I, Vance ML, Barkan A, Frohman L, Kleinberg DL.
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [Abstract] [Full Text] [Related]

  • 19. Neuroendocrine dysfunction in the acute phase of traumatic brain injury.
    Agha A, Rogers B, Mylotte D, Taleb F, Tormey W, Phillips J, Thompson CJ.
    Clin Endocrinol (Oxf); 2004 May; 60(5):584-91. PubMed ID: 15104561
    [Abstract] [Full Text] [Related]

  • 20. Pulsatile versus continuous intravenous administration of growth hormone (GH) in GH-deficient patients: effects on circulating insulin-like growth factor-I and metabolic indices.
    Jørgensen JO, Møller N, Lauritzen T, Christiansen JS.
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1616-23. PubMed ID: 2189886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.